Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding com…
Medical - Instruments & Supplies
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 28.67 | 655.62 | 509.54 | |
| Graham Fair Price | -71.33 | 5.46 | 19.05 | |
| PEG | 2626.53 | -11.21 | 0.41 | |
| Price/Book | 1.74 | 5.18 | 5.09 | |
| Price/Cash Flow | -49.76 | 280.91 | 559.15 | |
| Prices/Earnings | 1137.97 | 1218.60 | -98.44 | |
| Price/Sales | 4.66 | 67.44 | 64.44 | |
| Price/FCF | -49.76 | 280.91 | 559.15 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 14.09 | 0.50 | 0.43 | |
| Operating Margin | 135.63 | 0.01 | < 0.005 | |
| ROA | -91.86 | < 0.005 | < 0.005 | |
| ROE | -0.01 | < 0.005 | -91.78 | |
| ROIC | < 0.005 | < 0.005 | -26.45 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.04 | 0.70 | -94.76 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -1.18 | 3.29 | 177.74 | |
| EPS QOQ | -2.39 | 1.09 | -54.60 | |
| FCF QOQ | -0.41 | 1.02 | 152.72 | |
| Revenue QOQ | 0.10 | -0.03 | -72.61 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 206.60 | 233.31 | 12.93 | |
| Days Sales Outstanding (DSO) | 71.75 | 68.84 | -4.05 | |
| Inventory Turnover | 0.44 | 0.39 | -11.45 | |
| Debt/Capitalization | 0.23 | 0.27 | 18.99 | |
| Quick Ratio | 5.54 | 13.45 | 143.05 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 35.32 | 35.32 | 0.01 | |
| Cash | 13.46 | 40.93 | 204.03 | |
| Capex | -0.20 | -0.15 | 24.65 | |
| Free Cash Flow | 0.32 | 0.65 | 102.54 | |
| Revenue | 2.79 | 2.71 | -2.78 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad